Studies suggest that neuropeptide DSIP may have the potential to affect several neuroendocrine and neurophysiological processes. Research suggests that because of its potential to reduce oxidative stress and restore normal cardiac contractility, DSIP could be of great importance. Major depressive disorder therapy research has focused on the peptide as a possible target. Short and naturally occurring Delta sleep-inducing peptide (DSIP) is purported to be responsible for initiating sleep.
The chemical was initially isolated from the brains of rats during slow-wave sleep (in 1977), and its name comes from the fact that it may cause sleep in rabbits. Its endocrine and physiological activities have been steadily investigated. It suggests that DSIP may affect corticotropin levels, suppress somatostatin synthesis, lower stress, help maintain normal blood pressure, alter sleep patterns, and modify pain perception. The future of DSIP in the context of depression, cancer, and free radical damage prevention has been speculated in experimental research.
DSIP Peptide and Sleep
Extensive studies have suggested the peptide’s potential to induce sleep. Despite early observations in rabbits, it was challenging to establish a pattern of how DSIP may impact sleep. In certain research models, the peptide seemed to promote slower-wave sleep over paradoxical sleep. Interestingly, the study of other groups suggested that the molecule seemed to promote arousal in the first hour of sleep and drowsiness in the second. It was speculated that DSIP may potentially restore a healthy sleep routine by correcting cycle disruptions. The most important research on DSIP’s potential in regulating sleep has been done in the context of insomnia.
Findings suggest that this peptide may assist insomnia in chronic research models. Additional research suggests it may help chronic insomniac models go to sleep faster and have better-quality slumber. However, adequate study data is currently insufficient, despite polysomnographic studies suggesting that DSIP may generate statistically significant improvement in sleep. Subjective properties were seen in research models, including decreased tiredness, faster sleep initiation, and 59% more total sleep duration than placebo. The subjective findings were somewhat at odds with the EEG tests, which showed no signs of drowsiness. Existing testing procedures, such as EEG, quantify drowsiness based on pharmaceutical and not natural characteristics, which may account for the divergent results.
DSIP Peptide and Depression
Researchers have looked at DSIP to see whether it may play a part in the modulation of mitochondrial function in low-oxygen environments. Serotonin and monoamine oxidase A (MAO-A) levels were speculated to be protected by the peptide. This discovery provides more speculation that the peptide may influence the development of depression.
Research models of significant depression have been hypothesized to have reduced levels of DSIP in their cerebrospinal fluid compared to controls. Since depression and insomnia are so intertwined, any chemical that might help control the former could prove useful in mitigating the latter. However, there is currently no management strategy aimed at normalizing DSIP levels. However, findings imply it may impact suicidal behavior and has been related to changes in the hypothalamic-pituitary-adrenal axis.
DSIP Peptide and Muscle
Since its first discovery in the rabbit brain during slow-wave sleep, delta sleep-inducing peptide has been linked to sleep and the CNS-mediated regulation of sleep and wakefulness. Surprisingly, DSIP synthesis remains mostly unexplored. Because of its widespread distribution, including in the central nervous system, it is possible that the peptide’s main function is not sleep control. In addition to its role in inducing sleep, the hypothalamic hormone delta sleep-inducing peptide is thought to have other properties.
One research suggested that somatostatin, a protein produced by muscle cells that prevents muscle development, appeared to be reduced by Delta Sleep-Inducing Peptide. Scientists propose that delta sleep-inducing peptide may promote skeletal muscle hypertrophy and hyperplasia by blocking the hormone somatostatin. These direct inhibitory actions are somewhat surprising for a peptide long assumed to play predominantly in sleep promotion. This has led some to hypothesize that the peptide may affect physiology more broadly than previously thought.
In animal models, findings suggest that Delta sleep-inducing peptide (DSIP) may control blood pressure, heart rate, thermogenesis, and the lymphokine system. Some of these events happen before any sleep-related indications show up in the clinic or the lab, suggesting that Delta Sleep-Inducing Peptide may have a role in modifying physiology to get the organism ready for sleep. Preliminary studies suggest that the peptide may have high absorption when given to mice.
DSIP Peptide and Metabolism
Delta sleep-inducing peptide has been suggested to alter stress-related metabolic oscillations in rat models, which results in mitochondria switching from oxygen-dependent to oxygen-independent respiration. The latter is inefficient and leads to the production of harmful metabolic byproducts. Scientists propose that a stroke or heart attack research model may yield results from Delta sleep-inducing peptide since it has been suggested to stimulate oxidative phosphorylation even in low oxygen levels. To prevent tissues from further harm caused by oxygen deprivation until blood flow is restored, it seems to aid normal metabolic activity. Studies on Delta Sleep-Inducing Peptide (DSIP) have suggested promise as an anti-oxidant that may neutralize harmful free radicals and slow aging.
DSIP Peptide and Pain
Because of the promising results of a small-scale pre-clinical investigation, DSIP has been proposed as a viable agent in the context of chronic pain. Research suggests that research models who had been on long-term analgesics for a long time showed signs of withdrawal when they were not given anymore, but DSIP appeared to alleviate some of these symptoms.
Research in rats has suggested that opiates and DSIP may share the opiate receptors in the brain. Although it is not known whether the analgesic potential of DSIP is direct or indirect, the peptide may induce pain alleviation in a quantity-dependent way.
Scientists interested in further studying DSIP Peptide’s potential are encouraged to navigate to Biotech Peptides’ website for more high-quality research compounds and more educational articles about peptides, what they are, how they work, and their properties.
[i] Monnier M, Dudler L, Gächter R, Maier PF, Tobler HJ, Schoenenberger GA. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977 Apr 15;33(4):548-52. doi: 10.1007/BF01922266. PMID: 862769.
[ii] Nakagaki K, Ebihara S, Usui S, Honda Y, Takahashi Y, Kato N. [Effects of intraventricular injection of anti-DSIP serum on sleep in rats]. Yakubutsu Seishin Kodo. 1986 Jun;6(2):259-65. Japanese. PMID: 3776352.
[iii] Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988 May;85(10):3653-6. doi: 10.1073/pnas.85.10.3653. PMID: 3368469; PMCID: PMC280272.
[iv] Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. PMID: 6895513.
[v] Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. doi: 10.1159/000115716. PMID: 6548970.